13D Management Llc increased Armstrong World Inds Inc New (AWI) stake by 4.35% reported in 2017Q4 SEC filing. 13D Management Llc acquired 9,683 shares as Armstrong World Inds Inc New (AWI)’s stock declined 6.73%. The 13D Management Llc holds 232,435 shares with $14.07 million value, up from 222,752 last quarter. Armstrong World Inds Inc New now has $3.04B valuation. The stock increased 0.09% or $0.05 during the last trading session, reaching $57.15. About 10,462 shares traded. Armstrong World Industries, Inc. (NYSE:AWI) has risen 24.50% since April 17, 2017 and is uptrending. It has outperformed by 12.95% the S&P500.
Analysts expect RedHill Biopharma Ltd. (NASDAQ:RDHL) to report $-0.57 EPS on May, 2.They anticipate $0.07 EPS change or 14.00% from last quarter’s $-0.5 EPS. After having $-0.50 EPS previously, RedHill Biopharma Ltd.’s analysts see 14.00% EPS growth. It closed at $4.94 lastly. It is down 50.83% since April 17, 2017 and is downtrending. It has underperformed by 62.38% the S&P500.
Among 8 analysts covering RedHill Biopharma (NASDAQ:RDHL), 8 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. RedHill Biopharma had 14 analyst reports since July 29, 2015 according to SRatingsIntel. The firm earned “Buy” rating on Tuesday, September 29 by Northland Capital. The rating was maintained by H.C. Wainwright on Thursday, June 15 with “Buy”. The rating was initiated by Nomura on Tuesday, September 29 with “Buy”. Roth Capital maintained the stock with “Buy” rating in Monday, July 31 report. Zacks upgraded RedHill Biopharma Ltd. (NASDAQ:RDHL) on Saturday, August 22 to “Sell” rating. TH Capital maintained RedHill Biopharma Ltd. (NASDAQ:RDHL) rating on Wednesday, July 29. TH Capital has “Buy” rating and $31 target. The company was maintained on Tuesday, November 14 by Roth Capital. The company was maintained on Thursday, June 15 by FBR Capital. The rating was maintained by FBR Capital on Friday, February 24 with “Outperform”. As per Tuesday, August 25, the company rating was downgraded by TheStreet.
RedHill Biopharma Ltd., a specialty biopharmaceutical company, primarily focuses on the development and commercialization of late clinical-stage, proprietary, orally-administered, small molecule drugs for the treatment of gastrointestinal and inflammatory diseases, and cancer. The company has market cap of $108.95 million. The firm promotes two gastrointestinal products in the U.S., such as Donnatal, a prescription oral adjunctive drug used in the treatment of IBS and acute enterocolitis; and EnteraGam, a medical food intended for the dietary management under medical supervision of chronic diarrhea and loose stools. It currently has negative earnings. The Company’s clinical-stage pipeline includes TALICIA , an oral combination therapy for the treatment of Helicobacter pylori infection with successful results from a first Phase III study and an ongoing confirmatory Phase III study; RHB-104, an oral combination therapy for the treatment of Crohn's disease with an ongoing first Phase III study, a completed proof-of-concept Phase IIa study for multiple sclerosis, and QIDP status for nontuberculous mycobacteria infections; BEKINDA (RHB-102), a once-daily oral pill formulation of ondansetron with successful top-line results in a Phase III study for acute gastroenteritis and gastritis and an ongoing Phase II study for IBS-D; RHB-106, an encapsulated bowel preparation licensed to Salix Pharmaceuticals, Ltd.; YELIVA (ABC294640), a Phase II-stage, orally-administered, first-in-class SK2 selective inhibitor targeting multiple oncology, inflammatory, and gastrointestinal indications; MESUPRON, a Phase II-stage first-in-class, orally-administered protease inhibitor, targeting pancreatic cancer and other solid tumors; and RIZAPORT (RHB-103), an oral thin film formulation of rizatriptan for acute migraines, with a U.S.
Investors sentiment increased to 1.31 in 2017 Q4. Its up 0.19, from 1.12 in 2017Q3. It is positive, as 11 investors sold AWI shares while 63 reduced holdings. 43 funds opened positions while 54 raised stakes. 53.24 million shares or 6.33% less from 56.84 million shares in 2017Q3 were reported. Verition Fund Mgmt Limited Co owns 0.02% invested in Armstrong World Industries, Inc. (NYSE:AWI) for 3,761 shares. California Pub Employees Retirement System owns 142,663 shares. Adage Capital Ptnrs Gru Ltd Liability Corp owns 352,650 shares for 0.05% of their portfolio. First Trust Advsr LP reported 115,545 shares or 0.02% of all its holdings. Waterfront Cap Ltd Liability Corporation owns 181,576 shares. Renaissance Ltd Liability Co has 598,200 shares for 0.04% of their portfolio. Deutsche Bancorporation Ag holds 366,127 shares. Loomis Sayles Lp holds 0.06% or 465,896 shares. California State Teachers Retirement Sys holds 0.01% or 69,912 shares. Ny State Common Retirement Fund invested in 0.02% or 286,968 shares. Cubist Systematic Strategies Limited Liability owns 19,389 shares or 0.06% of their US portfolio. Bridger Mgmt Lc reported 874,481 shares or 3.49% of all its holdings. Gates Capital Management invested in 1.34 million shares or 1.95% of the stock. Beck Mack Oliver Limited Liability Corporation has 685,435 shares. The California-based Wells Fargo & Company Mn has invested 0% in Armstrong World Industries, Inc. (NYSE:AWI).
Since March 12, 2018, it had 0 buys, and 1 sale for $140.06 million activity. On Monday, March 12 ValueAct Holdings – L.P. sold $140.06M worth of Armstrong World Industries, Inc. (NYSE:AWI) or 2.35 million shares.
Among 17 analysts covering Armstrong World Industries (NYSE:AWI), 5 have Buy rating, 4 Sell and 8 Hold. Therefore 29% are positive. Armstrong World Industries had 38 analyst reports since July 31, 2015 according to SRatingsIntel. RBC Capital Markets maintained the shares of AWI in report on Monday, August 28 with “Hold” rating. On Friday, October 20 the stock rating was maintained by Citigroup with “Neutral”. On Wednesday, January 20 the stock rating was downgraded by Barclays Capital to “Underweight”. The stock of Armstrong World Industries, Inc. (NYSE:AWI) earned “Neutral” rating by Goldman Sachs on Tuesday, October 6. Jefferies maintained it with “Hold” rating and $62.0 target in Tuesday, February 27 report. The firm has “Buy” rating given on Wednesday, August 5 by Deutsche Bank. As per Tuesday, September 19, the company rating was maintained by KeyBanc Capital Markets. The firm has “Equal-Weight” rating by Barclays Capital given on Tuesday, October 13. The firm earned “Underperform” rating on Friday, September 23 by Bank of America. SunTrust maintained the stock with “Buy” rating in Friday, October 27 report.